Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review...

Descripción completa

Detalles Bibliográficos
Autores principales: Owji, Shayan, Caldas, Stella A, Ungar, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617518/
https://www.ncbi.nlm.nih.gov/pubmed/36316998
http://dx.doi.org/10.2147/JAA.S342051
_version_ 1784820860120465408
author Owji, Shayan
Caldas, Stella A
Ungar, Benjamin
author_facet Owji, Shayan
Caldas, Stella A
Ungar, Benjamin
author_sort Owji, Shayan
collection PubMed
description Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review is to summarize the efficacy and safety of ruxolitinib cream in patients with AD based on the available evidence. Overall, ruxolitinib cream demonstrated high efficacy and a favorable safety profile for treating atopic dermatitis.
format Online
Article
Text
id pubmed-9617518
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96175182022-10-30 Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib Owji, Shayan Caldas, Stella A Ungar, Benjamin J Asthma Allergy Review Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review is to summarize the efficacy and safety of ruxolitinib cream in patients with AD based on the available evidence. Overall, ruxolitinib cream demonstrated high efficacy and a favorable safety profile for treating atopic dermatitis. Dove 2022-10-25 /pmc/articles/PMC9617518/ /pubmed/36316998 http://dx.doi.org/10.2147/JAA.S342051 Text en © 2022 Owji et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Owji, Shayan
Caldas, Stella A
Ungar, Benjamin
Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
title Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
title_full Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
title_fullStr Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
title_full_unstemmed Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
title_short Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
title_sort management of atopic dermatitis: clinical utility of ruxolitinib
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617518/
https://www.ncbi.nlm.nih.gov/pubmed/36316998
http://dx.doi.org/10.2147/JAA.S342051
work_keys_str_mv AT owjishayan managementofatopicdermatitisclinicalutilityofruxolitinib
AT caldasstellaa managementofatopicdermatitisclinicalutilityofruxolitinib
AT ungarbenjamin managementofatopicdermatitisclinicalutilityofruxolitinib

Ejemplares similares